# FIBRIPHEN™ LRT

REF CK585K-RUO

Clotting method for quantitative determination of Fibrinogen,

with ready to use liquid reagents.

FOR RESEARCH USE ONLY.
DO NOT USE IN DIAGNOSTIC PROCEDURES.



155 rue d'Eragny, 95000 Neuville-sur-Oise, France Tél : +33 (0)1 34 40 65 10 Fax : +33 (0)1 34 48 72 36 www.hyphen-biomed.com info@hyphen-biomed.com

English, last revision: 10-2021

#### INTENDED USE:

The FIBRIPHEN™ LRT kit is a clotting method for *in vitro* quantitative determination of Fibrinogen in human citrated plasma (Clauss method), using manual or automated method.

Reagents are in the liquid presentation, ready to use (LRT, Liquid Reagent Technology).

This kit is for research use only and must not be used for patient diagnosis or treatment.

# **SUMMARY AND EXPLANATION:**

#### Technical:1

Fibrinogen is a 340 Kd soluble plasma glycoprotein, synthesized in the liver, containing 6 peptidic chains, with a 2 to 2 symmetry, and linked by disulfide bridges (2  $A\alpha$ , 2  $B\beta$  and  $2\gamma$  chains). Thrombin clots fibrinogen and forms fibrin, which is then stabilized by activated Factor XIII in presence of calcium. Fibrinogen is lysed by plasmin to fragments X and Y, first, then D and E.

#### PRINCIPLE:

In the presence of a constant and in excess amount of thrombin, the clotting time (CT) obtained for diluted citrated plasma depends on the plasma fibrinogen concentration.

# **REAGENTS:**

R Calcium Thrombin, from bovine origin (about 100 NIH/mL), liquid form. Contains BSA, an heparin neutralizing substance, preservatives and stabilizers.

6 vials of 5 mL.

# **WARNINGS AND PRECAUTIONS:**

- Some reagents provided in these kits contain materials of animal origin. Users of reagents of these types must exercise extreme care in full compliance with safety precautions in the manipulation of these biological materials as if they were infectious.
- Waste should be disposed of in accordance with applicable local regulations.
- Use only the reagents from the same batch of kits.
- Aging studies show that the reagents can be shipped at room temperature without degradation.
- This device of *in vitro* use is intended for professional use in the laboratory.

### REAGENT PREPARATION:

Reagent is ready to use; homogenize and load it directly on the analyzer following application guide instruction.

For manual method, allow to stabilize for 30 minutes at room temperature (18-25°C), homogenize before use.

### STORAGE AND STABILITY:

Unopened reagents should be stored at 2-8°C in their original packaging. Under these conditions, they can be used until the expiry date printed on the kit.

Reagent stability after opening, free from any contamination or evaporation, and stored closed, is of:

- 4 weeks at 2-8°C.
- 7 days at room temperature (18-25°C).
- Do not freeze.
- Stability on board of the analyzer: see the specific application.

# REAGENTS AND MATERIALS REQUIRED BUT NOT PROVIDED:

### Reagents:

- Distilled water.
- Imidazole Buffer (AR021B-RUO/AR021K-RUO/AR021L-RUO/AR021M-RUO/AR021N-RUO).

• Specific calibrators and controls with known titration, such as:

Product Name	Reference	
BIOPHEN™ Plasma Calibrator	222101-RUO	
BIOPHEN™ Normal Control Plasma	223201-RUO	
BIOPHEN™ Abnormal Control Plasma	223301-RUO	
EASYPLASMA™ Control Set	225601-RUO	
EASYPLASMA™ Calibrator	226601-RUO	

Also refer to the specific application guide of the analyzer used.

#### Materials:

- Electromagnetic water-bath, semi-automatic or automatic analyzer for clotting assays.
- · Stopwatch, calibrated pipettes, silicon glass or plastic test tubes.

# SPECIMEN COLLECTION AND PREPARATION:

The blood (9 volumes) should be carefully collected onto the trisodium citrate anticoagulant (1 volume) (0.109 M, 3.2%) by clean venipuncture. Discard the first tube.

Specimens should be prepared and stored in accordance with applicable local guidelines (for the United States, see the CLSI H21-A5<sup>2</sup> guideline for further information concerning specimen collection, handling and storage).

For plasma storage, please refer to references<sup>2,3</sup>.

# PROCEDURE:

The kit can be used in manual or automated method. Perform the test at  $37^{\circ}C$  and the clotting time, triggered by addition of the FIBRIPHEN<sup>TM</sup> LRT reagent, is measured.

For an automated method, application guides are available on request. See specific application guide and specific precautions for each analyzer.

# Assay method:

1. Reconstitute the calibrator and control as indicated in the specific instructions

Calibrator should be diluted in the Imidazole buffer. Prepare calibration points on the range about 0.7 to 7 g/L (C:4 - C:2 - C - 2C- 8C/3 fibrinogen in Imidazole buffer) for working dilution 1:10 (alternatively C:2 - C - 2C - 4C for working dilution 1:20 with manual method).

The 1:10 dilution (in automated method) or 1:20 (in manual method) of calibrator correspond to the "C" g/L concentration of fibrinogen ("C" defines the concentration of fibrinogen for commercial calibrator).

2. Dilute the specimens, calibrators and controls in Imidazole buffer, as described in the table below:

		Dilution		
Specimens	References	Manual method	Automated method	
Controls	223201-RUO / 223301-RUO / 225601-RUO	1:20	1:10	
Specimens to test	NA	1:20	1:10	

Establish the calibration curve and test it with the quality controls. If stored at room temperature (18-25°C), test the diluted specimens quickly. The exact calibrator and control concentrations for each batch are indicated on the flyer provided with the kit.

To ensure optimal performances of the assay, perform all assays (calibration, samples, controls) extemporaneously and successively without interruption.

#### 3. Introduce at 37°C:

	Volume			
Calibrator, specimens or controls diluted	100 μL			
Incubate at 37°C for 3 minutes, then add the following				
(starting the stop-watch):				
R Calcium Thrombin pre-incubated at 37°C	50 μL			
Record the exact clotting time CT (in seconds).				


If a reaction volume other than that specified above is required for the method used, the ratio of volumes must be strictly observed to guarantee assay performance. The user is responsible for validating any changes and their impact on all results.

#### CALIBRATION

The FIBRIPHEN™ LRT assay can be calibrated for the assay of fibrinogen. The calibrator covering the calibration range is available from HYPHEN BioMed (see the REAGENTS AND MATERIALS REQUIRED BUT NOT PROVIDED paragraph) and can be used to establish the calibration curve.

The calibration range is about 0.7 to 7 g/L (on Sysmex CS-series).

The calibration curve shown below is given by way of example only. The calibration curve established for the assay series must be used.



# **QUALITY CONTROL:**

The use of quality controls serves to validate method compliance, along with between-test assay homogeneity for a given batch of reagents.

Include the quality controls with each series, as per good laboratory practice, in order to validate the test. A new calibration curve should be established, preferably for each test series, and at least for each new reagent batch, or after analyzer maintenance, or when the measured quality control values fall outside the acceptance range for the method. Each laboratory must define its acceptance ranges and verify the expected performance in its analytical system.

### RESULTS:

- For the manual endpoint method, plot the calibration curve log-log, with the clotting time (sec) along the Y-axis and the Fibrinogen concentration, expressed as g/L, along the X-axis.
- The concentration of Fibrinogen (g/L) in the test specimen is directly inferred from the calibration curve, when the standard dilution is used.
- If other dilutions are used, the level obtained should be multiplied by the additional dilution factor used.

The results obtained should be for research use only and must not be used for patient diagnosis or treatment.

# LIMITATIONS:

- To ensure optimum test performance and to meet the specifications, the technical instructions validated by HYPHEN BioMed should be followed carefully.
- Any reagent presenting an unusual appearance or showing signs of contamination must be rejected.
- Any suspicious samples or those showing signs of activation must be rejected.
- Various substances can affect the results. An additional investigation should be realized to determine the origin of each unexpected or abnormal result, and the result should be confirmed by another method (e.g. fibrinogen antigenic assay).
- The obtained CT for a same sample and a same reagent lot can vary according to the instrument used and the clot detection mode.
- If obtained CT is too short (high concentration of fibrinogen), dilute more the plasma. If obtained CT is too long (low concentration of fibrinogen), dilute less the plasma.

#### **PERFORMANCES:**

- The measuring range depends on the analytical system used (about 0.25 to 12 g/L of fibrinogen on Sysmex CS-series, with redilution).
- Performance studies were conducted internally on Sysmex CS-5100.
   Performance was assessed using laboratory controls over a 20-day period, 2 series per day and 3 repetitions within each series for a control level. The following results were obtained:

Control		Intra assay			Inter assays			
Control	n	Mean	CV%	SD	n	Mean	CV%	SD
Normal level	40	2.56	2.7	0.07	120	2.54	1.7	0.04
Pathological level	40	0.93	2.2	0.02	120	0.92	2.4	0.02

 Correlation with reference method (FIBRIPHEN™ vs FIBRIPHEN™ LRT on Sysmex CS-5100):

n = 105 y = 1,043x - 0.100 r = 0.999

· Interferences:

No interference, on the analyzer Sysmex CS-series was observed with the molecules and up to following concentrations:

Hemoglobin	Bilirubin (F/C)	Heparins	Intralipids	
Hemograpin	Dimabin (170)	(UFH/LMWH)		
1100 mg/dL	10 / 30 mg/dL	2 IU/mL	200 mg/dL	
Rivaroxaban /	Arixtra			
	2 μg/mL			
FDP	Orgaran	Argatroban	D-Dimer	
130 µg/mL	2 μg/mL	1 μg/mL	50 μg/mL	

Also refer to the specific application guide of the analyzer used.

### **REFERENCES:**

- Mosesson M.W. Fibrinogen and fibrin structure and function. JTH. 2005.
- CLSI Document H21-A5: "Collection, transport, and processing of blood specimens for testing plasma -based coagulation assays and molecular hemostasis assays; approved guideline". 2008
- Woodhams B. et al. Stability of coagulation proteins in frozen plasma. Blood coagulation and Fibrinolysis. 2001.

### SYMBOLS:

Symbols used and signs listed in the ISO 15223-1 standard, see Symbol definitions document.

Changes compared to the previous version.